Flualprazolam is a tranquiliser of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring.
It was first synthesised in 1976, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified as such in Sweden in 2018. It can be described as the 2′-fluoro derivative of alprazolam, or the fluoro instead of chloro analogue of triazolam, and has similar sedative and anxiolytic effects.
Flualprazolam is banned in Sweden, also is illegal in the UK. In December 2019, the World Health Organisation recommended flualprazolam for international scheduling as a Schedule IV medication under the Convention on Psychotropic Substances.